302 related articles for article (PubMed ID: 22639342)
1. In vitro uses of human pluripotent stem cell-derived cardiomyocytes.
Matsa E; Denning C
J Cardiovasc Transl Res; 2012 Oct; 5(5):581-92. PubMed ID: 22639342
[TBL] [Abstract][Full Text] [Related]
2. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.
Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115
[TBL] [Abstract][Full Text] [Related]
3. Embryonic template-based generation and purification of pluripotent stem cell-derived cardiomyocytes for heart repair.
Dierickx P; Doevendans PA; Geijsen N; van Laake LW
J Cardiovasc Transl Res; 2012 Oct; 5(5):566-80. PubMed ID: 22806916
[TBL] [Abstract][Full Text] [Related]
4. An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures.
Ting S; Chen A; Reuveny S; Oh S
Stem Cell Res; 2014 Sep; 13(2):202-13. PubMed ID: 25043964
[TBL] [Abstract][Full Text] [Related]
5. The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.
Ye L; Ni X; Zhao ZA; Lei W; Hu S
J Cardiovasc Transl Res; 2018 Oct; 11(5):366-374. PubMed ID: 29845439
[TBL] [Abstract][Full Text] [Related]
6. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
7. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.
Holmgren G; Synnergren J; Bogestål Y; Améen C; Åkesson K; Holmgren S; Lindahl A; Sartipy P
Toxicology; 2015 Feb; 328():102-11. PubMed ID: 25529476
[TBL] [Abstract][Full Text] [Related]
9. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.
Mordwinkin NM; Burridge PW; Wu JC
J Cardiovasc Transl Res; 2013 Feb; 6(1):22-30. PubMed ID: 23229562
[TBL] [Abstract][Full Text] [Related]
10. Perspective on human pluripotent stem cell-derived cardiomyocytes in heart disease modeling and repair.
Li Q; Wang J; Wu Q; Cao N; Yang HT
Stem Cells Transl Med; 2020 Oct; 9(10):1121-1128. PubMed ID: 32725800
[TBL] [Abstract][Full Text] [Related]
11. Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.
Tan SH; Ye L
J Cardiovasc Transl Res; 2018 Oct; 11(5):375-392. PubMed ID: 29557052
[TBL] [Abstract][Full Text] [Related]
12. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: The New Working Horse in Cardiovascular Pharmacology?
Lemoine MD; Christ T
J Cardiovasc Pharmacol; 2021 Mar; 77(3):265-266. PubMed ID: 33433138
[No Abstract] [Full Text] [Related]
13. Modeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes.
Zanella F; Lyon RC; Sheikh F
Trends Cardiovasc Med; 2014 Jan; 24(1):32-44. PubMed ID: 24054750
[TBL] [Abstract][Full Text] [Related]
14. Maturation status of sarcomere structure and function in human iPSC-derived cardiac myocytes.
Bedada FB; Wheelwright M; Metzger JM
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1829-38. PubMed ID: 26578113
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening.
Dick E; Rajamohan D; Ronksley J; Denning C
Biochem Soc Trans; 2010 Aug; 38(4):1037-45. PubMed ID: 20659000
[TBL] [Abstract][Full Text] [Related]
16. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
Talbert DR; Doherty KR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Sci; 2015 Jan; 143(1):147-55. PubMed ID: 25304212
[TBL] [Abstract][Full Text] [Related]
17. High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.
Del Álamo JC; Lemons D; Serrano R; Savchenko A; Cerignoli F; Bodmer R; Mercola M
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1717-27. PubMed ID: 26952934
[TBL] [Abstract][Full Text] [Related]
18. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
19. Maturation strategies and limitations of induced pluripotent stem cell-derived cardiomyocytes.
Wu P; Deng G; Sai X; Guo H; Huang H; Zhu P
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 33057659
[TBL] [Abstract][Full Text] [Related]
20. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
